Sovaldi and trelagliptin in latest Japanese approvals
This article was originally published in Scrip
Japan has approved a batch of new drugs including Gilead's Sovaldi as part of the first all-oral therapy for HCV genotype 2 in the country, Eisai's Lenvima for thyroid cancer, and the world's first once-weekly DPP-4 inhibitor from Takeda.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.